CytomX Therapeutics Inc (NASDAQ:CTMX) – Stock analysts at Oppenheimer issued their FY2022 earnings estimates for CytomX Therapeutics in a research report issued to clients and investors on Wednesday. Oppenheimer analyst L. Cann anticipates that the biotechnology company will post earnings per share of ($2.66) for the year.
Other analysts also recently issued research reports about the company. Jefferies Group raised their price objective on CytomX Therapeutics to $40.00 and gave the stock a “buy” rating in a research note on Thursday, March 8th. Bank of America raised their price objective on CytomX Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, March 8th. Cantor Fitzgerald set a $40.00 price objective on CytomX Therapeutics and gave the stock a “buy” rating in a research note on Thursday, March 8th. Citigroup started coverage on CytomX Therapeutics in a research note on Friday, January 5th. They set a “buy” rating and a $40.00 price objective on the stock. Finally, BidaskClub raised CytomX Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, December 15th. Three research analysts have rated the stock with a sell rating, two have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. CytomX Therapeutics has an average rating of “Buy” and a consensus price target of $35.67.
Shares of CytomX Therapeutics (NASDAQ CTMX) traded up $0.99 during trading on Monday, reaching $34.03. The company had a trading volume of 861,824 shares, compared to its average volume of 372,258. The firm has a market cap of $1,321.27, a P/E ratio of -28.68 and a beta of 0.76. CytomX Therapeutics has a twelve month low of $13.00 and a twelve month high of $35.00.
Several institutional investors and hedge funds have recently added to or reduced their stakes in CTMX. Perceptive Advisors LLC raised its stake in shares of CytomX Therapeutics by 79.1% in the 4th quarter. Perceptive Advisors LLC now owns 2,490,381 shares of the biotechnology company’s stock valued at $52,571,000 after purchasing an additional 1,100,000 shares during the period. BlackRock Inc. grew its holdings in shares of CytomX Therapeutics by 28.5% in the 4th quarter. BlackRock Inc. now owns 2,646,599 shares of the biotechnology company’s stock valued at $55,870,000 after acquiring an additional 586,698 shares in the last quarter. Millennium Management LLC grew its holdings in shares of CytomX Therapeutics by 34.0% in the 4th quarter. Millennium Management LLC now owns 837,415 shares of the biotechnology company’s stock valued at $17,678,000 after acquiring an additional 212,423 shares in the last quarter. Nexthera Capital LP bought a new position in shares of CytomX Therapeutics in the 4th quarter valued at about $3,797,000. Finally, Renaissance Technologies LLC grew its holdings in shares of CytomX Therapeutics by 32.9% in the 4th quarter. Renaissance Technologies LLC now owns 715,100 shares of the biotechnology company’s stock valued at $15,096,000 after acquiring an additional 177,200 shares in the last quarter. 78.50% of the stock is currently owned by hedge funds and other institutional investors.
In other CytomX Therapeutics news, CFO Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $21.11, for a total value of $52,775.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Sean A. Mccarthy sold 13,052 shares of CytomX Therapeutics stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $21.04, for a total value of $274,614.08. Following the completion of the sale, the insider now directly owns 17,695 shares in the company, valued at approximately $372,302.80. The disclosure for this sale can be found here. Insiders sold a total of 132,626 shares of company stock worth $3,709,830 in the last three months. Company insiders own 8.00% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.thelincolnianonline.com/2018/03/14/analysts-issue-forecasts-for-cytomx-therapeutics-incs-fy2022-earnings-ctmx.html.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.